LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

HomeStock ListBioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc

Closed

Sector Healthcare

92.14 0.68

Overview

Share price change

24h

Current

Min

90.72

Max

93.21

Key metrics

By Trading Economics

Income

-20M

20M

Sales

65M

646M

P/E

Sector Avg

125.462

23.904

EPS

0.18

Profit margin

3.153

Employees

3,401

EBITDA

3.7M

55M

Recommendations

By TipRanks

Rating Consensus

Buy

12 Months Forecast

+17.97 upside

Dividends

By Dow Jones

Next earnings

24 Apr 2024

Market Stats

By TradingEconomics

Market Cap

-28M

16B

Previous open

91.46

Previous close

92.14

News Sentiment

By Acuity

100%

0%

267 / 274 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

BioMarin Pharmaceutical Inc chart

Related News

12 Apr 2024, 19:17 UTC

Earnings

Trending: JPMorgan Chase Shares Down After 1Q Results

12 Apr 2024, 17:52 UTC

Major Market Movers

Chinese EV Stocks Sink After Senator Calls For Import Ban

12 Apr 2024, 22:35 UTC

Acquisitions, Mergers, TakeOvers

Cisco Completes Acquisition Of Isovalent To Define The Future Of Multicloud Networking And Security >CSCO

12 Apr 2024, 21:56 UTC

Market Talk

Large Companies Embrace Climate-Tech Investing -- Market Talk

12 Apr 2024, 21:08 UTC

Market Talk

Mexican Stocks Close Lower; Peso Loses Ground Against Dollar -- Market Talk

12 Apr 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

12 Apr 2024, 20:46 UTC

Top News

Dow Falls, Logs Worst Week Since March 2023 -- WSJ

12 Apr 2024, 20:44 UTC

Earnings

High Rates Have Been a Profit Machine For Banks. Not Anymore. -- Update

12 Apr 2024, 20:42 UTC

Earnings

High Rates Have Been a Profit Machine For Banks. Not Anymore. -- Update

12 Apr 2024, 20:37 UTC

Earnings

These Stocks Moved the Most Today: JPMorgan Chase, Citigroup, AMD, Intel, Arista Networks, Zoetis, and More -- Barrons.com

12 Apr 2024, 19:35 UTC

Market Talk

U.S. Natural Gas Futures Little Changed in Sideways Trade -- Market Talk

12 Apr 2024, 19:11 UTC

Market Talk

Oil Futures Settle Higher, But With Weekly Losses -- Market Talk

12 Apr 2024, 18:40 UTC

Market Talk

P&G Volume Growth Seen Offsetting Some Challenges -- Market Talk

12 Apr 2024, 17:52 UTC

Market Talk

BMO Scales Back Bank Of Canada Rate-Cut Outlook -- Market Talk

12 Apr 2024, 17:32 UTC

Market Talk

U.S. Oil Rig Count Falls By Two To 506 - -- Market Talk

12 Apr 2024, 16:38 UTC

Earnings

High Rates Have Been a Profit Machine For Banks. Not Anymore. -- WSJ

12 Apr 2024, 16:27 UTC

Market Talk

Netflix's Boost From Password Crackdown Seen As Underappreciated -- Market Talk

12 Apr 2024, 16:25 UTC

Market Talk

SPDR Gold Rises On Expected Iranian Attack On Israel -- Market Talk

12 Apr 2024, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

12 Apr 2024, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

12 Apr 2024, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

12 Apr 2024, 16:10 UTC

Market Talk

Crude Oil Futures Come Off Highs in Jittery Trade -- Market Talk

12 Apr 2024, 16:08 UTC

Market Talk

Energy Activity Contracts in 1Q, KC Fed Says -- Market Talk

12 Apr 2024, 16:03 UTC

Acquisitions, Mergers, TakeOvers

Arista Network Stock Gets a Rare Double Downgrade. Analyst Says It's Time to Sell. -- Barrons.com

12 Apr 2024, 15:51 UTC

Market Talk

Gold Futures Set New Record as Markets Focus on Geopolitics, Debt and Inflation -- Market Talk

12 Apr 2024, 15:08 UTC

Market Talk

ASML Expected to Post Healthy 1Q Order Intake -- Market Talk

12 Apr 2024, 15:08 UTC

Market Talk

Global Equities Roundup: Market Talk

12 Apr 2024, 14:38 UTC

Market Talk

Number of People Who Think They'll Never Own A Home Rises -- Market Talk

12 Apr 2024, 14:10 UTC

Market Talk

ECB June Rate Cut Looks Certain, Future Cuts Depend on Inflation -- Market Talk

12 Apr 2024, 14:06 UTC

Top News

China Tells Telecom Carriers to Phase Out Foreign Chips in Blow to Intel, AMD -- Update

Peer Comparison

Price change

BioMarin Pharmaceutical Inc forecast

Price Target

By TipRanks

17.97% upside

12 Months Forecast

Average 108.79 USD  17.97%

High 138 USD

Low 80 USD

Based on 20 Wall Street analysts offering 12 month price targets for BioMarin Pharmaceutical Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

20 ratings

14

Buy

6

Hold

0

Sell

Technical Score

By Trading Central

87.1 / N/A Support&Resistance

Short Team

Strong Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

267 / 274 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.